Lexicon Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Lexicon Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#347 of 15,742 sponsors by registered trial count).
Lexicon Pharmaceuticals: 56 sponsored US clinical trials, 1 recruiting.
Lexicon Pharmaceuticals sponsors 56 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 51 completed. 17 of these trials are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Type 2 Diabetes Mellitus, with 3 trials.
Top-decile sponsor footprint
Lexicon Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#347 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
51 of 55 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
56 total, page 1 of 2
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
NCT06481891
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
NCT06203002
Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
NCT04662281
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04455633
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
NCT03521934
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
NCT03386344
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
NCT03315143
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
NCT03292653
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy
NCT03332771
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
NCT03423446
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
NCT03351478
A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects
NCT03302845
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
NCT03285594
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
NCT03242252
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
NCT03242018
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
NCT03066830
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
NCT02926937
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
NCT02926950
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
NCT02647918
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone
NCT02531035
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
NCT02459899
PK Study of Sotagliflozin in Subjects With Hepatic Impairment
NCT02471274
Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C
NCT02383940
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
NCT02384941
Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
NCT02373046
DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin
NCT02300363
DDI Study With Multiple-dose LX4211 and Single Dose Digoxin
NCT02300350
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
NCT02195635
An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
NCT02157558
An Open-Label Food Effect Study of Telotristat Etiprate
NCT02157584
A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects
NCT02147808
A Thorough QT Study of Telotristat Etiprate
NCT02155205
Telotristat Etiprate for Carcinoid Syndrome Therapy
NCT02063659
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
NCT02026063
Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects
NCT01916850
Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects
NCT01916863
Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects
NCT01913002
Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects
NCT01818232
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
NCT01742208
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
NCT01677910
Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
NCT01528111
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
NCT01555008
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
NCT01494233
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
NCT01456052
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
NCT01441232
A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis
NCT01417052
An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects
NCT01411800
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
NCT01376557
A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects
NCT01334242
A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects
NCT01292993
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 25 |
| Phase 2 | 14 |
| Phase 3 | 17 |
What is open in the Lexicon Pharmaceuticals pipeline
1 recruiting of 56 indexed (2% open); 51 completed (91%).
Phase mix: 17 late (III/IV) vs 39 early (I/II) (early-phase heavy).
Top condition: Type 2 Diabetes Mellitus (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Lexicon Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 56 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Lexicon Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 56 trials (± recruiting share)
- Edwards Lifesciences · 57 trials · 18% recruiting
- St. Luke's-Roosevelt Hospital Center · 57 trials · 0% recruiting
- Supernus Pharmaceuticals · 57 trials · 11% recruiting
- USDA Grand Forks Human Nutrition Research Center · 57 trials · 4% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Alcon Research · 2% recruiting · 275 trials
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · 2% recruiting · 55 trials
- Eisai · 2% recruiting · 287 trials
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
Related
What to do with this Lexicon Pharmaceuticals page
56 registered trials is a research-attention snapshot, not an endorsement of Lexicon Pharmaceuticals or any single study.
- 1 of Lexicon Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Type 2 Diabetes Mellitus is the condition Lexicon Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 2 Diabetes Mellitus trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Lexicon Pharmaceuticals pipeline card: 56 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.